The use of ovarian reserve markers in IVF clinical practice: a national consensus

References

• La Marca A, Grisendi V, Giulini S, et al. Individualization of the FSH starting dose in IVF/ICSI cycles using the antral follicle count. J Ovarian Res 2013;6:11
   PubMed Web of Science ®Google Scholar
• La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation inIVF using ovarian reserve markers: from theory to practice. Hum Reprod Update 2014;20:124–40
   PubMed Web of Science ®Google Scholar
• Nelson SM, Yates RW, Lyall H, et al. Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum Reprod 2009;24:867–75
   PubMed Web of Science ®Google Scholar
• Yates AP, Rustamov O, Roberts SA, et al. Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF. Hum Reprod 2011;26:2353–62
   PubMed Web of Science ®Google Scholar
• Broekmans FJ, Kwee J, Hendriks DJ, et al. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 2006;12:685–718
   PubMed Web of Science ®Google Scholar
• Iliodromiti S, Kelsey TW, Wu O, et al. The predictive accuracy of anti-Müllerian hormone for live birth after assisted conception: a systematic review and meta-analysis of the literature. Hum Reprod Update 2014;20:560–70
   PubMed Web of Science ®Google Scholar
• La Marca A, Papaleo E, Grisendi V, et al. Development of a nomogram based on markers of ovarian reserve for the individualisation of the follicle-stimulating hormone starting dose in in vitro fertilisation cycles. BJOG 2012;119:1171–9
   PubMed Web of Science ®Google Scholar
• Fleming R, Broekmans F, Calhaz-Jorge C, et al. Can anti-Müllerian hormone concentrations be used to determine gonadotrophin dose and treatment protocol for ovarian stimulation? Reprod Biomed Online 2013;26:431–9
   PubMed Web of Science ®Google Scholar
• La Marca A, Sighinolfi G, Radi D, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2010;16:113–30
   PubMed Web of Science ®Google Scholar
• Wallace WH, Kelsey TW. Human ovarian reserve from conception to the menopause. PLoS One 2010;5:e8772
   PubMed Web of Science ®Google Scholar
• Rosen MP, Johnstone E, Addauan-Andersen C, Cedars MI. A lower antral follicle count is associated with infertility. Fertil Steril 2011;95:1950–4
   PubMed Web of Science ®Google Scholar
• Peñarrubia J, Fábregues F, Manau D, et al. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist – gonadotropin treatment. Hum Reprod 2005;20:915–22
   PubMed Web of Science ®Google Scholar
• van Rooij IA, Broekmans FJ, te Velde ER, et al. Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 2002;17:3065–71
   PubMed Web of Science ®Google Scholar
• Seifer DB, MacLaughlin DT, Christian BP, et al. Early follicular serum Müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 2002;77:468–71
   PubMed Web of Science ®Google Scholar
• La Marca A, Giulini S, Tirelli A, et al. Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod 2007;22:766–71
   PubMed Web of Science ®Google Scholar
• Nelson SM, Yates RW, Fleming R. Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles – implications for individualization of therapy. Hum Reprod 2007;22:2414–21
   PubMed Web of Science ®Google Scholar
• Burger HG, Dudley E, Mamers P, et al. Early follicular phase serum FSH as a function of age: the roles of inhibin B, inhibin A and estradiol. Climacteric 2000;3:17–24
   PubMedGoogle Scholar
• Toner JP, Philput CB, Jones GS, Muasher SJ. Basal follicle-stimulating hormone level is a better predictor of in vitro fertilization performance than age. Fertil Steril 1991;55:784–91
   PubMed Web of Science ®Google Scholar
• Broer SL, Dólleman M, Opmeer BC, et al. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Hum Reprod Update 2011;17:46–54
   PubMed Web of Science ®Google Scholar
• Broer SL, van Disseldorp J, Broeze KA, et al. IMPORT study group. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update 2013;19:26–36
   PubMed Web of Science ®Google Scholar
• Rowe G, Wright G. The Delphi technique as a forecasting tool: issues and analysis. Int J Forecast 1999;15:353–75
   Web of Science ®Google Scholar
• Graham B, Regehr G, Wright JG. Delphi as a method to establish consensus for diagnostic criteria. J Clin Epidemiol 2003;56:1150–6
   PubMed Web of Science ®Google Scholar
• Fehr A, Thürmann P, Razum O. Expert Delphi survey on research and development into drugs for neglected diseases. BMC Health Serv Res 2011;11:312
   PubMed Web of Science ®Google Scholar
• Fitch K, Bernstein S, Aguilar M. The RAND/UCLA appropriateness method user’s manual. Santa Monica, CA: RAND; 2001
   Google Scholar
• den Breejen EME, Nelen WLDM, Schol SFE, et al. Development of guideline-based Indicators for patient-centredness in fertility care: what patients add. Hum Reprod 2013;28:987–96
   PubMed Web of Science ®Google Scholar
• Istituto Superiore di Sanità - Rome-Italy. www.iss.it. http://www.iss.it/site/registropma/PUB/Centri/CentriPMA.aspx [last accessed Mar 2013]
   Google Scholar
• Ferraretti AP, La Marca A, Fauser BC, et al. ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod 2011;26:1616–24
   PubMed Web of Science ®Google Scholar
• Lee TH, Liu CH, Huang CC, et al. Serum anti-Müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Reprod 2008;23:160–7
   PubMed Web of Science ®Google Scholar
• Nardo LG, Gelbaya TA, Wilkinson H, et al. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization. Fertil Steril 2009;92:1586–93
   PubMed Web of Science ®Google Scholar
• Aflatoonian A, Oskouian H, Ahmadi S, Oskouian L. Prediction of high ovarian response to controlled ovarian hyperstimulation: anti-Müllerian hormone versus small antral follicle count (2–6 mm). J Assist Reprod Genet 2009;26:319–25
   PubMed Web of Science ®Google Scholar
• Ocal P, Sahmay S, Cetin M, et al. Serum anti-Müllerian hormone and antral follicle count as predictive markers of OHSS in ART cycles. J Assist Reprod Genet 2011;28:1197–203
   PubMed Web of Science ®Google Scholar
• Polyzos NP, Tournaye H, Guzman L, et al. Predictors of ovarian response in women treated with corifollitropin alfa for in vitro fertilization/intracytoplasmic sperm injection. Fertil Steril 2013;100:430–7
   PubMed Web of Science ®Google Scholar